Tuesday, October 29, 2024 4:14:18 PM
It's massive as he said it was if all this comes to pass, despite the current sp. My plan is to chill and accumulate until volume picks up
500% Growth Target Has Been Set For The Next Six Months of Operations
MELBOURNE, Fla., Oct. 1, 2024 /PRNewswire/ -- Branded Legacy, Inc.,(OTC.PK: BLEG) a leading supplier of botanical extracts and alkaloid-based compounds, is excited to announce that it has sent its first invoice to Monster Group, Inc. a multinational product manufacturer and distributor generating over $70,000,000 in annual revenue. This partnership marks a significant milestone and is expected to act as a catalyst that will propel Branded Legacy into generating over $10,000,000 annually in revenue by 2025.
The partnership commences with Branded Legacy's subsidiary Sycamore BioPharma providing high-quality mitragynine salt, which will be integrated into the client's product lines which are sold across the Middle East, Europe, and North America. Branded Legacy will take over lab operations for this client over the next 6 to 10 months. The current supply line is generating approximately $60,000 weekly for the company, and a 500% growth target has been set for the next six months of operations. Discussions for expanding the product line with several additional commodities are already underway.
In addition, Branded Legacy's subsidiary Royal Biotek has been engaged in negotiations with a large distributor to provide Delta 8 and Delta 9 distillate, which could lead to similar revenue figures in the near future.
"This announcement is the culmination of months of dedicated work and negotiations," said Dave Oswald, CEO of Branded Legacy, Inc. "While we have always been cautious about sharing sensitive deal information until it's finalized, I'm pleased to confirm that this development positions us to be a self-funded company moving forward, reducing the need to seek additional funding."
Branded Legacy has also been in talks with several potential acquisition candidates, with discussions accelerating rapidly. These candidates include companies that complement Branded Legacys' existing operations and strategic growth plans.
BLEG $$$
500% Growth Target Has Been Set For The Next Six Months of Operations
MELBOURNE, Fla., Oct. 1, 2024 /PRNewswire/ -- Branded Legacy, Inc.,(OTC.PK: BLEG) a leading supplier of botanical extracts and alkaloid-based compounds, is excited to announce that it has sent its first invoice to Monster Group, Inc. a multinational product manufacturer and distributor generating over $70,000,000 in annual revenue. This partnership marks a significant milestone and is expected to act as a catalyst that will propel Branded Legacy into generating over $10,000,000 annually in revenue by 2025.
The partnership commences with Branded Legacy's subsidiary Sycamore BioPharma providing high-quality mitragynine salt, which will be integrated into the client's product lines which are sold across the Middle East, Europe, and North America. Branded Legacy will take over lab operations for this client over the next 6 to 10 months. The current supply line is generating approximately $60,000 weekly for the company, and a 500% growth target has been set for the next six months of operations. Discussions for expanding the product line with several additional commodities are already underway.
In addition, Branded Legacy's subsidiary Royal Biotek has been engaged in negotiations with a large distributor to provide Delta 8 and Delta 9 distillate, which could lead to similar revenue figures in the near future.
"This announcement is the culmination of months of dedicated work and negotiations," said Dave Oswald, CEO of Branded Legacy, Inc. "While we have always been cautious about sharing sensitive deal information until it's finalized, I'm pleased to confirm that this development positions us to be a self-funded company moving forward, reducing the need to seek additional funding."
Branded Legacy has also been in talks with several potential acquisition candidates, with discussions accelerating rapidly. These candidates include companies that complement Branded Legacys' existing operations and strategic growth plans.
BLEG $$$
Bullish
Recent BLEG News
- Branded Legacy, Inc. (OTC: BLEG) Successfully Negotiates Retirement of Four Additional Convertible Notes, Preventing Potential Dilution of Hundreds of Millions of Shares • InvestorsHub NewsWire • 02/04/2026 02:07:00 PM
- Branded Legacy, Inc. (OTC: BLEG) Successfully Negotiates Retirement of Four Additional Convertible Notes, Preventing Potential Dilution of Hundreds of Millions of Shares • GlobeNewswire Inc. • 02/04/2026 02:07:00 PM
- Branded Legacy, Inc. Announces Successful Retirement of Legacy Convertible Debt as New Management Focuses on Balance Sheet Optimization and OTC Yield Sign Removal • InvestorsHub NewsWire • 12/29/2025 01:30:00 PM
- Branded Legacy, Inc. Announces Successful Retirement of Legacy Convertible Debt as New Management Focuses on Balance Sheet Optimization and OTC Yield Sign Removal • GlobeNewswire Inc. • 12/29/2025 01:30:00 PM
- Branded Legacy, Inc. Announces Complete Management Overhaul and Strategic Reset Under New Leadership • GlobeNewswire Inc. • 12/10/2025 02:17:29 PM
- Branded Legacy, Inc. Announces Complete Management Overhaul and Strategic Reset Under New Leadership • InvestorsHub NewsWire • 12/10/2025 02:00:00 PM
- Branded Legacy Announces Strong Revenues from Newly Acquired Pau Hana Subsidiary • GlobeNewswire Inc. • 11/25/2025 03:38:40 PM
- Branded Legacy Announces Strong Revenues from Newly Acquired Pau Hana Subsidiary • InvestorsHub NewsWire • 11/25/2025 03:11:49 PM
- Branded Legacy, Inc. Advances Revolutionary Intranasal Drug Delivery with Unitary Device Mold Development • GlobeNewswire Inc. • 10/27/2025 12:30:00 PM
- Branded Legacy, Inc. Advances Revolutionary Intranasal Drug Delivery with Unitary Device Mold Development • InvestorsHub NewsWire • 10/27/2025 12:30:00 PM
- Branded Legacy, Inc. (OTC: BLEG) Advances Life-Saving Innovation with FDA Pre-ANDA Briefing for Revolutionary Intranasal Naloxone Spray • GlobeNewswire Inc. • 10/22/2025 03:17:40 PM
- Branded Legacy, Inc. (OTC: BLEG) Advances Life-Saving Innovation with FDA Pre-ANDA Briefing for Revolutionary Intranasal Naloxone Spray • InvestorsHub NewsWire • 10/22/2025 02:56:16 PM
- Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market • InvestorsHub NewsWire • 09/30/2025 12:30:00 PM
- Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market • GlobeNewswire Inc. • 09/30/2025 12:30:00 PM
- Branded Legacy Inc. Unveils Cutting-Edge GMP Facility to Accelerate Life-Saving Inhaled Naloxone Development • GlobeNewswire Inc. • 09/23/2025 02:44:55 PM
- Branded Legacy Inc. Unveils Cutting-Edge GMP Facility to Accelerate Life-Saving Inhaled Naloxone Development • InvestorsHub NewsWire • 09/23/2025 01:40:59 PM
- Branded Legacy, Inc. Expands Capabilities with Acquisition of State-of-the-Art GMP Facility in Vancouver • InvestorsHub NewsWire • 09/04/2025 12:30:00 PM
- Branded Legacy, Inc. Forms Strategic Partnership with Stanford University's Dr. Eran Bendavid to Advance Addiction Solutions • InvestorsHub NewsWire • 08/22/2025 05:39:40 PM
- Branded Legacy, Inc. Partners with McMaster University: Revolutionizing Addiction Treatment Through Cutting-Edge Clinical Research and Regulatory Pathways • InvestorsHub NewsWire • 08/19/2025 12:39:04 PM
- Branded Legacy, Inc. Finalizes Transformative Acquisition of Bio Legacy Evaluative Group (f/k/a Menlo Health), Unlocking Explosive Growth Potential in Biotech and Drug Delivery • InvestorsHub NewsWire • 08/12/2025 12:30:00 PM
- Branded Legacy, Inc. Signs Letter of Intent to Acquire Bio-Legacy Evaluative Group, Advancing Innovations in Intranasal Drug Delivery • InvestorsHub NewsWire • 07/29/2025 12:30:00 PM
- Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue • InvestorsHub NewsWire • 07/14/2025 05:23:12 PM
